Scientists achieve first rewire of genetic switches
Researchers in Manchester have successfully carried out the first rewire of genetic switches, creating what could be a vital tool for the development of new drugs and even future gene therapies. A team of scientists from the School of chemistry and the Manchester Interdisciplinary Biocentre (MIB) at The University of Manchester have found a way of hijacking so-called 'riboswitches' and directing gene activity.
Working within cells of bacteria, chemical biologist Professor Jason Micklefield and his team have rewired these genetic switches so they are no longer activated by small naturally occurring molecules found in cells – but through the addition of a synthetic molecule. The work builds on the recent discovery that these naturally occurring molecules can turn genes on and off by triggering riboswitches found within a large molecule called 'messenger RNA'. The research was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and Selective Chemical Intervention in Biological Systems Initiative.
In the latest research, when Manchester researchers added synthetic molecules, they bound to the riboswitches and caused the genes to spark into life. The findings are reported in the latest edition of Proceedings of the National Academy of Sciences (PNAS).
The Manchester team monitored how successfully they had re-wired the cells by observing the creation of a gene product that makes the cells glow green.
Dr Neil Dixon, a senior researcher in the team, said: "Being able to selectively activate and regulate genes could have tremendous impact in drug discovery and the emerging field of synthetic biology. "This technology could be used to turn on and off important biological pathways and processes, leading to a deeper understanding of how cells function. The next big challenge is to apply this technology to study biological processes within human cells. This could allow us to discover more about our hugely complex biological selves.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Butylscopolamine
LDC and Roche will jointly advance innovative drug discovery projects - LDC Enters new Industry Partnership for the Discovery of Novel Medicines
Scientists identify genes that control smooth muscle contraction
